Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, February 11 '25)

Image
By G.M.

 


    Ann Intern Med

  1. IOANNOU GN, Berry K, Rajeevan N, Li Y, et al
    Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation.
    Ann Intern Med. 2025 Feb 4. doi: 10.7326/ANNALS-24-01015.
    PubMed         Abstract available


    Antiviral Res

  2. UEHARA T, Yotsuyanagi H, Ohmagari N, Doi Y, et al
    Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CL(pro) detected in the SCORPIO-SR phase 3 trial.
    Antiviral Res. 2025 Jan 30:106097. doi: 10.1016/j.antiviral.2025.106097.
    PubMed         Abstract available


    Clin Infect Dis

  3. SMITH EA, Javier GM, Multani A, Beaird OE, et al
    Anti-SARS-CoV-2 IgG Antibody Titers in Cotemporary lots of Intravenous Immune Globulin and Fresh Frozen Plasma Compared to COVID Convalescent Plasma.
    Clin Infect Dis. 2025 Feb 3:ciaf045. doi: 10.1093.
    PubMed         Abstract available

  4. REGAN AK, Rowe SL, Sullivan SG, Coates MM, et al
    Coronavirus Disease 2019 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients.
    Clin Infect Dis. 2025 Feb 5:ciae580. doi: 10.1093.
    PubMed         Abstract available

  5. MANDEL H, Yoo YJ, Allen AJ, Abedian S, et al
    Long-COVID incidence proportion in adults and children between 2020 and 2024.
    Clin Infect Dis. 2025 Feb 5:ciaf046. doi: 10.1093.
    PubMed         Abstract available


    J Infect

  6. QUINT JK, Dube S, Carty L, Yokota R, et al
    Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study.
    J Infect. 2025 Jan 29:106432. doi: 10.1016/j.jinf.2025.106432.
    PubMed         Abstract available


    J Med Virol

  7. ZODDA E, Pons M, DeMoya-Valenzuela N, Calvo-Gonzalez C, et al
    Induction of the Inflammasome by the SARS-CoV-2 Accessory Protein ORF9b, Abrogated by Small-Molecule ORF9b Homodimerization Inhibitors.
    J Med Virol. 2025;97:e70145.
    PubMed         Abstract available

  8. CHANG S, Shin J, Park S, Park H, et al
    Continuous Tracking for Effective Tackling: Ad5/35 Platform-Based JN1 Lineage Vaccines Development in Response to Evolving SARS-CoV-2 Variants.
    J Med Virol. 2025;97:e70206.
    PubMed         Abstract available

  9. SUN J, Cheng J, Shi D, Xu X, et al
    Genetic Epidemiology of Porcine Epidemic Diarrhea Virus Circulating in China From 2010 to 2024: Characterization of Phylogenetic and Genetic Diversity of S1-Based Genes.
    J Med Virol. 2025;97:e70198.
    PubMed         Abstract available

  10. PENG Y, Zhang Y, Zeng S, Cai C, et al
    A Comprehensive Pan-Cancer Analysis of COVID-19 Booster Vaccination Efficacy and Safety.
    J Med Virol. 2025;97:e70211.
    PubMed        


    J Virol

  11. KUHN AJ, Outlaw VK, Marcink TC, Yu Z, et al
    Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development.
    J Virol. 2025 Feb 4:e0215924. doi: 10.1128/jvi.02159.
    PubMed         Abstract available

  12. PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al
    Diversifying T-cell responses: safeguarding against pandemic influenza with mosaic nucleoprotein.
    J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867.
    PubMed         Abstract available

  13. WANG X, Dong M, Wu X, Schnepf D, et al
    Single-cell transcriptomics reveals a compartmentalized antiviral interferon response in the nasal epithelium of mice.
    J Virol. 2025 Feb 4:e0141324. doi: 10.1128/jvi.01413.
    PubMed         Abstract available

  14. PHAN T, Ribeiro RM, Edelstein GE, Boucau J, et al
    Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.
    J Virol. 2025 Feb 4:e0162324. doi: 10.1128/jvi.01623.
    PubMed         Abstract available


    Lancet Infect Dis

  15. WANG Q, Mellis IA, Wu M, Bowen A, et al
    KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2.
    Lancet Infect Dis. 2025 Feb 4:S1473-3099(25)00058.
    PubMed        

  16. SUTHAR MS, Manning KE, Ellis ML, Jain S, et al
    The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant.
    Lancet Infect Dis. 2025 Jan 31:S1473-3099(25)00007.
    PubMed        

  17. XIE Y
    COVID-19 versus influenza: the need to align policies with COVID-19 realities.
    Lancet Infect Dis. 2025 Jan 29:S1473-3099(25)00001.
    PubMed        

  18. BAGER P, Svalgaard IB, Lomholt FK, Emborg HD, et al
    The hospital and mortality burden of COVID-19 compared with influenza in Denmark: a national observational cohort study, 2022-24.
    Lancet Infect Dis. 2025 Jan 29:S1473-3099(24)00806.
    PubMed         Abstract available

  19. LIU J, Yu Y, Yang S, Jian F, et al
    Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1.
    Lancet Infect Dis. 2025 Jan 28:S1473-3099(25)00015.
    PubMed        


    Nature

  20. LEDFORD H
    Four lessons COVID taught us about the immune system.
    Nature. 2025;638:19-20.
    PubMed        

  21. LEE S, Yu Y, Trimpert J, Benthani F, et al
    Author Correction: Virus-induced senescence is a driver and therapeutic target in COVID-19.
    Nature. 2025 Feb 4. doi: 10.1038/s41586-025-08718.
    PubMed        

  22. CHEMAITELLY H, Ayoub HH, Coyle P, Tang P, et al
    Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron.
    Nature. 2025 Feb 5. doi: 10.1038/s41586-024-08511.
    PubMed         Abstract available


    Radiology

  23. WEIR-MCCALL JR, Bell JS
    COVID-19 Infection and Coronary Plaque Progression: An Early Warning of a Potential Public Health Crisis.
    Radiology. 2025;314:e243767.
    PubMed        

  24. DAI N, Tang X, Hu Y, Lu H, et al
    SARS-CoV-2 Infection Association with Atherosclerotic Plaque Progression at Coronary CT Angiography and Adverse Cardiovascular Events.
    Radiology. 2025;314:e240876.
    PubMed         Abstract available


    Science

  25. GOSTIN LO, Meier BM
    A world less safe and secure.
    Science. 2025;387:559.
    PubMed         Abstract available


    Travel Med Infect Dis

  26. PLAZA PI, Lambertucci SA
    Differences between Influenza H5N1, A/H1N1 2009, and SARS-CoV-2 in a pandemic risk scenario.
    Travel Med Infect Dis. 2025 Jan 31:102811. doi: 10.1016/j.tmaid.2025.102811.
    PubMed        


    Zhonghua Jie He He Hu Xi Za Zhi

  27. WANG T, Chen X, Shi XP, He YX, et al
    [COVID-19 infection with tracheobronchomalacia: a case report].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:138-141.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »